



Express Mail. No.: **EV 452 777 175 US**

**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	BRÖGMANN, Bianca et al.	Confirmation No.:	1883
Serial No.:	10/510,673	Art Unit:	1623
Filing Date:	May 23, 2005	Examiner:	To Be Assigned
Title:	MATRIX FOR SUSTAINED, INVARIANT AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS	Attorney Docket No: (CAM No.:	6750-309-999 305158-999300)

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

Enclosures accompanying this Information Disclosure Statement are the following:

1. A Substitute Form 1449/PTO entitled Information Disclosure Statement by Applicant listing References **A01-A04, B01-B06 and C01-C07**;
2. Copies of References B01-B06 and C01-C07.

Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of References **A01-A04**, which are United States patent documents, are not being submitted unless required by the Office.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of a first Office Action on the merits. Therefore, no fee is believed to be due for this Information Disclosure Statement. If any fee is believed to be due, however, the Commissioner is hereby authorized to charge any such fees that may be due to Jones Day Deposit Account No. 50-3013.

No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made. 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: March 2, 2006

*Gidon Stern / by Ian Scott Reg. No. 44,827*  
Gidon D. Stern 

---

 27,469  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, N.Y. 10017-6702  
212-326-3939

Enclosures



<p>S000ubstitute for Form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p>	ATTY DOCKET NO.	APPLICATION NO.
	6750-309-999	10/510,673
	APPLICANT: Brögmann et al.	
	FILING DATE: May 23, 2005	ART UNIT: CONF. NO.: 1623 1883

### U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A01	3,773,955	11/20/1973	Pachter et al.	
A02	3,966,040	06/29/1976	Pachter et al.	
A03	4,457,933	07/03/1984	Gordon et al.	
A04	4,582,835	04/05/1986	Lewis et al.	

### FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
					YES	NO
B01	EP 0 352 361	01/31/1990	The Rockefeller University			
B02	EP 0 527 638	02/17/1993	Euro Celtique S.A.			
B03	EP 0 631 781	01/04/1995	Euro Celtique S.A.			
B04	EP 0 699 436	03/06/1996	Euro Celtique S.A.			
B05	DE 43 25 465	02/02/1995	Zens et al. (in German, w/ English abstract)			
B06	WO 97/45091	12/04/1997	Euro Celtique S.A.			

### NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.,), date, page(s)s, volume, publisher, city and/or country where published., etc.)

EXAMINER'S INITIALS*	
C01	Cherry et al., "Opioids in pain therapy," The Frankfurt Consensus, STK - Special Issue 2001 Article 2 (3 pages)
C02	Ebell et al., "The management of pain in cancer patients," Supportive Measures in Oncology, Jahn et al., eds., 1994, vol. 3
C03	Forth et al., General and Special Pharmacology and Toxicology, 7th rev. ed., 1996, pp. 207-217 (in German, w/ English translation)
C04	Neuenschwander et al., Palliative Medicine At A Glance, 1999 (whole book)
C05	Oxygesic® Product Information, 1997-2001 (in German, w/ English translation)
C06	Valoron® Product Information, 1997-2001 (in German, w/ English translation)
C07	Zech et al., "Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study," Pain, 1995 Oct;63(1):65-76

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	